Herpes simplex virus-1 has been identified as the trigger factor in certain cases of NMDA-receptor autoimmune encephalitis. We report on a 67-year-old female patient, who was severely affected by post-herpetic NMDA-receptor autoimmune encephalitis. Her symptoms did not improve under methylprednisolone pulse therapy and plasma exchange under acyclovir prophylaxis. She received protein A immunoadsorption and a long-term immunosuppression with rituximab. Under treatment, activated T-cells as well as B-and plasma cells decreased in peripheral blood and cerebrospinal fluid, and anti-NMDA-R IgG titers in serum and cerebrospinal fluid declined with near complete cessation of intrathecal autoantibody synthesis. The patient regained near complete independence and profoundly improved on formal neuropsychological assessment. Despite reduction of antiviral defense through of lowered activated T cells and concomitantly decreasing HSVspecific IgG antibodies, no evidence of viral reactivation was detected.
INTRODUCTION
In certain cases, relapsing symptoms following Herpes simplex virus-1 (HSV1) encephalitis are caused by the formation of autoantibodies directed against the GluN1 subunit of the human NMDA-receptor (NMDA-R), linking autoimmune and infective pathologies [1, 2] . Previously reported treatment options include methylprednisolone pulse therapy (MP), plasma exchange (PLEX) and most recently rituximab or cyclophosphamide under acyclovir prophylaxis [3] . Whilst patients with this dual pathology often suffer from residual deficits due to the HSV1 infection, immunosuppressive treatment can improve new or worsening symptoms caused by the autoimmune pathology [4] . Here, we present a patient with severe relapsing symptoms refractory to MP and PLEX, but with a remarkable improvement through protein A immunoadsorption (IA) [5] and rituximab.
CASE REPORT
A 67-year-old Caucasian woman, who was diagnosed with HSV1 encephalitis with positive HSV1-PCR in CSF as the cause of aphasia and reduced consciousness 3 months prior. Her preceding medical history was otherwise unremarkable. Following a steady improvement under antiviral and rehabilitation therapy, her caregivers reported a subsequent acute decline in cognitive and motor abilities. Clinical examination on admission to our hospital (T = 0 M, Fig. 1 and disorientated. She was aphasic and unable to verbally or non-verbally communicate. Muscle tone was increased with generalized rigidity, rendering the patient non-ambulatory. Under treatment with MP and PLEX, symptoms remained unchanged for 14 days but improved continuously under IA. Following acute treatment, the patient was discharged to a rehabilitation facility. She returned three months later (T = 3 M, Fig. 1 ) with a recurrence of the same clinical presentation. Treatment consisted of 14 days of MP and PLEX, which again did not change the symptoms. Once more, improvement could only be achieved through IA. On first presentation (T = 0 M, Fig. 1 ) and relapse (T = 3 M, Fig. 1 ), MRI showed temporal scarring predominantly on the right side caused by previous HSV1 infection, but no signs of viral reactivation or other acute pathologies (Fig. 1A) .
Initial routine CSF analysis (T = 0M, Fig. 1 ) yielded a normal lymphocyte count (3/μl), elevated protein (793 mg/l), normal albumin ratio (7.6 × 10 ), increased intrathecal IgG-synthesis (74%) and type 3 oligoclonal bands (OCB) (Fig. 1C and I ). During relapse (T = 3 M, Fig. 1 ), CSF analysis showed normal values for lymphocyte count (2/μl), CSF protein (433 mg/l) and albumin ratio (5.7 × 10 −3 ), increased intrathecal IgG synthesis (89%) and type 3 OCB ( Fig. 1C and I ). Flow cytometry [6] at first presentation (T = 0M, Fig. 1F and G) . Anti-NMDA-R IgG titers and ASI declined (T = 9 M: serum 1:100, CSF 1:100, ASI 235; T = 15: serum 1:100, CSF 1:100, ASI 4.8) (Fig. 1H and I ), illustrating fading of intrathecal anti-NMDA-R IgG synthesis [7] . Despite immunotherapy, HSV-ASI declined to 6.8 (T = 9 M, Fig. 1 ) and 3.9 (T = 15 M, Fig.1 ), respectively, and no evidence of viral reactivation was found throughout follow-up with a consistently negative HSV1-PCR in CSF. Formal neuropsychological assessment (NPA) [8] was first possible at initiation of rituximab treatment (T = 3 M, Fig. 1 ) in a limited fashion (digit span forwards and backwards, phonematic verbal fluency, word production test) and showed severe deficits in attention span, executive functions and language abilities. During treatment, the patient's cognitive and motor abilities improved consistently. She was able to walk without support and to complete the activities of daily living nearly independently. At the 15 months follow-up (T = 15 M, Fig. 1 ), whilst NPA performance had improved in all tests, certain residual deficits remained (Fig. 1J) . MRI at the 15 months follow-up (T = 15 M, Fig. 1 ) demonstrated bilateral temporal atrophy, more pronounced on the right side (Fig. 1A ). There were no adverse events under rituximab therapy.
DISCUSSION
Several studies have established that HSV1 encephalitis can trigger encephalitis with anti-NMDA-R autoantibodies [1, 2] . The infective form commonly antedates the autoimmune form, yet it remains uncertain which facet of HSV infection drives the autoimmune response. Testing for anti-NMDA-R antibodies in patients with relapses following HSV-encephalitis is recommended [9] . Overall the occurrence of such cases is rare, hence standardized treatment recommendations are not available yet. Treatment attempts regularly include antiviral and immunosuppressive agents, including combinations of acyclovir, steroids with and without PLEX [10] and secondary immunotherapy including rituximab or cyclophosphamide under acyclovir prophylaxis [3] . Patients with post-herpetic NMDA-autoimmune encephalitis often suffer from residual deficits due to the HSV1 infection and experience new or worsening symptoms through NMDA-R-autoantibody formation.
Immunosuppressive treatment can improve NMD-R autoantibody mediated symptoms hence it is recommended once the diagnosis is established [4] . Patients with classic NMDA-R autoimmune encephalitis have been shown to recover to full health or minor residual deficits in up to 75% of cases [11, 12] , it remains uncertain whether the prognosis of post-herpetic NMDA-R autoimmunencephalitis is as favorable. We describe an adult female patient suffering from severe relapsing postherpetic anti-NMDA-R encephalitis, which failed to respond to MP and PLEX but improved remarkably under IA followed by induction of rituximab treatment at relapse. Both methods of therapeutic apheresis (PLEX and IA) have emerged as possible treatment options for autoimmune encephalitis [13] . In our case, IA seemed to be more effective as improvement occurred with short latency following this therapy. This could be test were calculated from internal control group data (N = 26). Note: In (C) and (I), circled data points are referenced by the lefthand y-axis (y1), whereas squared data points by the righthand y-axis (y2). Data T = −3 M is not shown, since the patient was not treated at our hospital at that stage.
explained by the very effective removal of intrathecal autoantibodies by IA as reported recently [5] , however, a cumulative effect of PLEX and IA cannot be fully ruled out as both methods were applied subsequently at both times in this patient. During maintenance treatment, activated T-cells as well as B-and plasma cells decreased in PB and CSF. Anti-NMDA-R IgG titers in PB and CSF declined with near complete cessation of intrathecal autoantibody synthesis. Despite reduction of activated T cells in PB and CSF and concomitant decreasing HSV IgG ASI, no evidence of viral reactivation was detected under treatment with rituximab. Cognitive and motor abilities increased, as demonstrated by NPA and improvement on modified Rankin scale, which declined from 5 to 2 within 12 months. Hence, rituximab in combination with IA, presents a possible treatment option for refractory post-herpetic NMDA-encephalitis as previously reported [3] . However, further research in an increased number of patients is needed regarding its efficacy and safety. 
FUNDING

